RIGL · Rigel Pharmaceuticals Inc
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 27, 2024; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Rigel reported Q2 net product sales of $67.0 million (+14% YoY) and net income of $17.3 million, in-licensed and is preparing the mid-August U.S. launch of VEPPANU, and raised its 2026 total revenue guidance to $285–$295 million while reiterating an expected full-year profit.
- + Net product sales rose 14% YoY to $67.0 million in Q2 2026.
- + TAVALISSE net product sales grew 18% YoY to $47.4 million.
- + REZLIDHIA net product sales grew 27% YoY to $8.9 million.
- + Rigel raised 2026 total revenue guidance to approximately $285–$295 million from the prior $275–$290 million range.
- + VEPPANU in-license expands commercial portfolio, with U.S. commercial availability expected in mid-August.
- + Company continues to anticipate positive full-year 2026 net income while funding new and existing programs.
- − Q2 net income fell to $17.3 million from $59.6 million a year ago, due largely to a prior-year $40.0M Lilly collaboration release.
- − GAVRETO net product sales declined 10% YoY to $10.7 million.
- − Total costs and expenses rose 36% YoY to $55.1 million, driven by higher personnel, R&D, and Arvinas/Pfizer-license costs.
- − Cash, cash equivalents and short-term investments fell to $95.3 million at June 30, 2026 from $155.0 million at December 31, 2025, partly reflecting a $70.0 million upfront payment to Arvinas and Pfizer.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RIGL
this stock
Rigel Pharmaceuticals Inc
|
$882.44M | +10.3% | +64.1% | 2.8 | 17.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 27, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RIGL | -2.6% | +15.8% | +82.0% | +2.3% | +10.3% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -1.5% | +17.6% | +64.1% | +2.7% | -1.8% |